Results 141 to 150 of about 5,281 (177)
Some of the next articles are maybe not open access.
Urate-lowering therapy for asymptomatic hyperuricaemia: A need for caution
Seminars in Arthritis and Rheumatism, 2017The observed associations of hyperuricaemia with hypertension, cardiovascular disease and kidney disease are receiving increasing interest. The potential role of urate-lowering therapy in the management of these "non-gout diseases" has been raised, and in some countries it is already recommended.
Stamp, L, Dalbeth, Nicola
openaire +3 more sources
Rheumatology International, 2017
Reduction of urate depositions in the joints, on dual-energy computed tomography (DECT), in patients with gout during urate-lowering therapy (ULT) was demonstrated in previous studies. The aim of this study was to further investigate the changes in distribution of urate deposits during ULT.
Zhuojun, Zhang +8 more
openaire +2 more sources
Reduction of urate depositions in the joints, on dual-energy computed tomography (DECT), in patients with gout during urate-lowering therapy (ULT) was demonstrated in previous studies. The aim of this study was to further investigate the changes in distribution of urate deposits during ULT.
Zhuojun, Zhang +8 more
openaire +2 more sources
[Gout: an overview of available urate lowering therapies].
Annales pharmaceutiques francaises, 2012The aim of urate-lowering therapy is to maintain urate concentration below the saturation point for monosodium urate. This therapy dissolves crystal deposits and cures gout while it is maintained. EULAR guidelines recommend that plasma urate should be maintained at a concentration less than 360μM, and the British Guidelines less than 300μM.
openaire +2 more sources
Adherence and persistence to urate-lowering therapies in the Irish setting
Clinical Rheumatology, 2014To identify adherence and persistence levels with urate-lowering therapies using the national administrative pharmacy claim database. This was a retrospective, pharmacy claims-based analysis of dispensed anti-gout medications on the Irish national HSE-PCRS scheme database between January 2008 and December 2012.
Bernie, McGowan +3 more
openaire +2 more sources
Influence of urate-lowering therapies on renal handling of uric acid
Clinical Rheumatology, 2014The purpose of this study is to investigate the effect of urate-lowering therapies (ULTs) on renal uric acid excretion in gout patients. This prospective observational study involved 106 primary gout patients and 51 healthy controls. Gout patients received ULT with either xanthine oxidase inhibitors or the uricosuric agent benzbromarone.
Lili, Ma +6 more
openaire +2 more sources
Gradual reduction of tophaceous deposits during urate-lowering therapy
Joint Bone Spine, 2021Sara Nysom Christiansen +3 more
openaire +3 more sources
Benefits of urate-lowering therapy in asymptomatic hyperuricemia
Evidence-Based Practice, 2022Alexandria Cooke, Hannah King
openaire +1 more source
Initiation of Urate Lowering Therapy (ULT)
The Singapore Family Physician, 2022openaire +1 more source
Radiation therapy‐associated toxicity: Etiology, management, and prevention
Ca-A Cancer Journal for Clinicians, 2021Kyle Wang
exaly